OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Hamid on the Use of Lifileucel in Advanced Melanoma

April 16th 2024

Omid Hamid, MD on adoptive T cell therapy, lifileucel, for patients with patients with advanced melanoma.

Dr Vallieres on the Role of Induction Therapy on Surgical Candidacy in Lung Cancer

April 16th 2024

Eric Vallieres, MD, FRCSC, discusses the impact of induction therapy on surgical candidacy and operative complexity in patients with thoracic malignancies.

Dr Piulats on Predictive Biomarkers for Treatment With Talazoparib/Enzalutamide in mCRPC

April 16th 2024

Josep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.

Dr Srour on the Utility of CTX130 in RCC

April 16th 2024

Samer A. Srour, MB ChB, MS, discusses the utility of the CAR T-cell therapy CTX130 and unmet needs in advanced clear cell renal cell carcinoma.

Dr Pearse on the Utility of Pirtobrutinib in Relapsed/Refractory MCL

April 16th 2024

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Agustí Garcia on the Rationale for the MELISA Trial in Ovarian Cancer

April 15th 2024

Núria Agustí Garcia, MD, discusses the MELISA trial, which is evaluating further steps toward lymphadenectomy replacement in ovarian cancer.

Dr Sekeres on the Rationale for the FDA Approval of Momelotinib in Myelofibrosis

April 15th 2024

Mikkael A. Sekeres, MD, MS, discusses the background on the FDA approval of momelotinib for the treatment of patients with anemic myelofibrosis.

Dr Levy on Multidisciplinary Treatment in Lung Cancer Care

April 15th 2024

Benjamin Levy, MD, discusses the utility of multidisciplinary treatment in lung cancer care.

Dr Ferrajoli on Shared Decision-Making During BTK Inhibitor Selection in Hematologic Malignancies

April 15th 2024

Alessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.

Dr Usmani on the Risk-Benefit Profile of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 15th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the risk-benefit profile of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Grivas on Frontline Treatment Options in Metastatic RCC

April 12th 2024

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

Dr Ball on the Use of Luspatercept in MDS With Anemia

April 12th 2024

Somedeb Ball, MBBS, discusses the benefits of luspatercept for patients with anemia due to a myelodysplastic syndrome.

Dr Koo on Challenges With PSMA PET in Prostate Cancer

April 12th 2024

Phillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.

Dr Smith on Next Steps With the KELIM Score and HIPEC in Epithelial Ovarian Cancer

April 12th 2024

Gabriella Smith, MD, discusses the predictive value of KELIM for survival outcomes with HIPEC at the time of surgery in epithelial ovarian cancer.

Dr Sekeres on Using MDS Risk-Stratification Systems in Clinical Practice

April 12th 2024

Mikkael A. Sekeres, MD, MS, discusses the utility of myelodysplastic syndromes risk stratification systems.

Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple Myeloma

April 12th 2024

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Dr Park on the Assessment of Robot-Assisted Nipple Sparing Mastectomy in Breast Cancer

April 12th 2024

Ko Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.

Dr Gangat on the Evolution of JAK Inhibitors in Myelofibrosis

April 12th 2024

Naseema Gangat, MBBS, on evolution of JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Cobain on Second- and Later-Line Treatment Options in HR+/HER2– Breast Cancer

April 12th 2024

Erin Frances Cobain, MD, on second-line treatment options for patients with HR-positive, HER2-negative metastatic breast cancer.

Dr Kasi on the Use of ctDNA to Help Inform Adjuvant Treatment Decisions in CRC

April 12th 2024

Pashtoon Murtaza Kasi, MD, M.S on the potential of ctDNA to guide further adjuvant treatment decisions in CRC and other tumor types.